Genmab — Januar 2023
-
-
Og så kører 1042 jo nu også i flere kombier med kemo, og har en arm med bugspytkirtlen også. https://clinicaltrials.gov/ct2/show/NCT04083599?term=Gen1042&draw=2&rank=1
-
Tirsdagens danske avisuddrag med Vestas, elbiler og kapitalfonde https://www.proinvestor.com/investornyt/922276/tirsdagens-danske-avisuddrag-med-vestas-elbiler-og-kapitalfonde
-
Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Talquetamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma https://www.globenewswire.com/news-release/2023/01/03/2581869/0/en/Janssen-Submits-Marketing-Authorisation-Application-to-the-European-Medicines-Agency-Seeking-Approval-of-Talquetamab-for-the-Treatment-of-Patients-with-Relapsed-or-Refractory-Multi.html
-
-
Transactions with shares and linked
securities in Genmab A/S made by managerial employees and their closely associated persons https://www.proinvestor.com/investornyt/922570/transactions-with-shares-and-linked-securities-in-genmab-a-s-made-by-managerial-employees-and-their-closely-associated-persons -
USA/lukning: Apple og Tesla ødelagde nytårsfesten https://www.proinvestor.com/investornyt/922650/usa-lukning-apple-og-tesla-odelagde-nytarsfesten
-
Genmab A/S (NASDAQ:GMAB - Get Rating) had its target price increased by investment analysts at JPMorgan Chase & Co. from 3,450.00 to 3,600.00 in a research note issued on Tuesday, The Fly reports. The firm currently has an "overweight" rating on the stock. https://www.marketbeat.com/instant-alerts/nasdaq-gmab-a-buy-or-sell-right-now-2023-01/
-
Hummingbird -which previously tried to work with Genmab's Duobody technology- now wants to try Synaffix ADC tech, just like Genmab. Funny that Genmabs deal with Synaffix was also on Jan 4, last year
https://hummingbirdbioscience.com/hummingbird-bioscience-and-synaffix-enter-license-agreement-to-develop-a-next-generation-antibody-drug-conjugate-adc-program/ -
J&J Q4 resultat 24 jan. https://www.jnj.com/johnson-johnson-to-host-investor-conference-call-on-fourth-quarter-results_
-
Ser frem til konferencen i næste uge. Mon ikke vi bliver lidt klogere på 1046 og især 1042. Det var jo nogle gevaldige udvidelser af studiet vi så fornylig. Og R&D dagen bragte ikke meget nyt. Jeg tror de kører på med begge stoffer, og at vi snart kan varme op til store forventninger til 1042.
-
Godmorgen.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind